Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of cases. It includes several subtypes and can cause symptoms like persistent cough, chest pain, and difficulty breathing.
AMG 193 for Advanced Non-Small Cell Lung Cancer
We are studying a new treatment, AMG 193, for patients with advanced non-small cell lung cancer that has a specific genetic deletion. The trial aims to evaluate its safety and effectiveness compared to existing options.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have metastatic or unresectable locally advanced non-small cell lung cancer?
- Have you received at least one prior treatment for your cancer and had it come back or not improve?
- Do you have brain metastases that have been treated and are at least 14 days since treatment?
- Have you had any major surgery in the last 28 days?
- Do you have untreated symptomatic brain metastases or asymptomatic brain metastases larger than 2 cm?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Amg 193
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Respiratory Oncology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Pulmonology
Ledeberg, Belgium
Algemeen Ziekenhuis Delta
Pulmonology
Rumbeke, Belgium
Sponsor: Amgen Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.